Edition:
United Kingdom

Concordia International Corp (CXRX.OQ)

CXRX.OQ on NASDAQ Stock Exchange Global Select Market

0.71USD
4:39pm GMT
Change (% chg)

$0.01 (+1.29%)
Prev Close
$0.70
Open
$0.70
Day's High
$0.71
Day's Low
$0.69
Volume
3,053
Avg. Vol
92,683
52-wk High
$3.52
52-wk Low
$0.45

Chart for

About

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Concordia International To Defer Payment Of About $37.5 Mln Interest Due Dec 15

* CONCORDIA INTERNATIONAL CORP - ‍DETERMINED TO DEFER PAYMENT OF APPROXIMATELY $37.5 MILLION OF INTEREST DUE DEC 15 ON 9.5% SENIOR UNSECURED NOTES​

15 Dec 2017

Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

LONDON Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

21 Nov 2017

Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

LONDON Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

21 Nov 2017

UPDATE 1-Drug firm Concordia overcharged Britain's health service with 6,000 pct price rise

LONDON, Nov 21 Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

21 Nov 2017

Britain says Canada's Concordia overcharging health service for thyroid drug

LONDON, Nov 21 Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

21 Nov 2017

BRIEF-Concordia International ‍comments on UK CMA statement of objections related to Liothyronine

* ‍COMMENTS ON CMA STATEMENT OF OBJECTIONS RELATED TO LIOTHYRONINE; SAYS "DO NOT BELIEVE THAT COMPETITION LAW HAS BEEN INFRINGED​"

21 Nov 2017

BRIEF-Concordia International Q3 ‍reported revenue $154.6 mln

* Concordia International announces third quarter 2017 results

14 Nov 2017

BRIEF-Concordia International seeks to realign capital structure under CBCA

* Concordia International Corp. takes next step to realign its capital structure by commencing proceedings under the Canada Business Corporations Act

20 Oct 2017

BRIEF-Concordia International - ‍decided to use a 30-day grace period to defer payment of about $26 million

* Concordia International - ‍decided to use a 30-day grace period to defer payment of about $26 million of interest due oct 16 on its $735 million unsecured notes​

16 Oct 2017

BRIEF-Concordia International-‍ UK CMA investigating into co's international segment

* Concordia International-‍ UK CMA investigating issues related to UK pharmaceutical sector, co's international segment,certain products part of inquiry​

11 Oct 2017

Earnings vs. Estimates